B
ECAUSE GENOMIC AND PROTEOMIC research in TBI is still very much an emerging field, our goal was not to recommend assays of specific protein biomarkers or polymorphisms as core data elements. The aim of the working group was to provide recommendations for core biospecimen and biomarker data elements for TBI research and develop best practice guidelines to standardize the quality and accessibility of these specimens. We were also charged with establishing consensus for the core specimen data elements that should be collected for every TBI study and to identify supplemental and emerging data elements for more advanced and extended studies.
APPROACH
Multiple group conference calls were held as well as a number of smaller group calls and e-mail interactions. There was universal agreement on the need for standardization and development of best practices for collecting, processing, and storing biospecimens and biofluids. Past, current, and future efforts in civilian and military TBI biomarker genomics and proteomics research were reviewed and discussed.
Two series of observations support the fundamental hypothesis that genetic factors significantly influence functional outcome after TBI. The first of these is the finding that inheritance of the APOE-e4 allele is associated with poor outcome after TBI. 1, 2 The effect size of inheritance of one APOE-e4 allele is modest, with the odds ratio of an unfavorable outcome ranging from 3.57 to 13.93. While these and other studies have primarily focused on 6-month outcome, 3 there is evidence that the APOE-e4 genotype may also be associated with long-term outcome and cognitive decline after TBI. 4 Thus, this polymorphism may be relevant in the patient with chronic as well as acute TBI. Polymorphisms in the interleukin-1 system have also been associated with outcome after TBI, but these studies have not so far been replicated. 5 It is likely that the small sample sizes used in studies to date are a factor in false-
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apolipoprotein E4 CDE common data element COMT catechol O-methyltransferase DNA deoxyribonucleic acid EDTA ethylenediaminetetraacetic acid EVD external ventricular drain LP lumbar puncture PBMC peripheral blood mononuclear cell RBC red blood cell TBI traumatic brain injury negative and even false-positive findings. 6 Although APOE-e4 appears to be the most likely candidate for the first "Core" genomic biomarker for TBI, future studies with sufficient patient numbers and comprehensive phenotyping are needed. There are also recent examples of discovery-driven proteomic studies focused on finding effective biomarkers for TBI. 7, 8 Mass spectrometry has been the primary proteomic technology and has revolutionized the ways that biomarker discovery is being conducted in this field.
Genomic biomarkers may also be relevant to psychologic health issues associated with TBI. For example, the COMT gene plays a key role in the degradation of dopamine in the frontal cortex. The Val
158
Met polymorphism in the COMT gene has been associated with neuropsychiatric phenotypes and cognition. 9, 10 The Val
Met genotype has also been associated with executive functioning in patients with TBI. 11 Recent studies have also identified an association between serotonin transporter genotype and posttraumatic stress disorder, 12 suggesting that this and other polymorphisms may help us understand the complicated interrelationship between TBI and psychologic health.
It was the consensus of the group that while there is significant potential for large-scale genomics and proteomics in TBI, there is sufficient variability in TBI biospecimen collection, processing, and storage that must be addressed to advance the field. 13, 14 Prospective clinical trials are an ideal setting in which to collect DNA and biological fluids in sufficiently large sample sizes associated with carefully collected clinical data to allow successful genomic and proteomic studies.
A due diligence process was carried out to explore similar efforts in other fields. A number of groups have already developed best practice guidelines for biospecimen resources.
15-18 These documents provide general principles that can be used to guide the design of studies in which biospecimens will be analyzed. There was general agreement that much of the groundwork for the TBI biospecimen working group had been provided by these prior efforts. It was acknowledged that the group should not reinvent the wheel, but it was also recognized that there are issues particular to TBI that should be considered and addressed. The group felt that a document that built on past efforts and incorporated issues relevant to TBI would be an important contribution to the literature and the research community. Based on the members' individual expertise, the participants divided into subgroups to address various aspects of biofluid and biomarker specimen collection, storage, and processing. Preliminary recommendations were developed through e-mail interactions with the focus groups and discussed in person with the working group members at the interagency workshop on Standardization of Data Collection in TBI and Psychological Health held in Washington, DC, in March 2009. The refined draft recommendations and best practices were presented to stakeholders and other working groups during the workshop for additional input. These comments and suggestions have also been incorporated in the current recommendations. The product of the Biospecimens and Biomarkers Working Group is, by its nature, different from the other TBI CDE Working Group articles in that the focus is best practices with step-by-step protocols to standardize sample collection, processing, and storage.
RECOMMENDATIONS FOR COMMON DATA ELEMENTS FOR BIOSPECIMENS AND BIOMARKERS
The following are the group's recommendations for core specimen data elements that should be collected for all studies. The collection of supplemental and emerging data elements recommended for more advanced and extended studies should be encouraged, particularly in studies that are directed at a molecular mechanism that the biomarker measures. The timing of DNA collection is less critical, even in patients who have received a blood transfusion. Recommendations for plasma and serum guidelines for proteomic and metabolomic analyses are shown in appendix 2. The timing for acquiring these samples is more complicated. An acute plasma sample (defined as Ͻ24h) was recommended by the Working Group as "Core" for all TBI studies to provide the opportunity for the identification of diagnostic and predictive biomarkers in large series of patients. However, the frequency and duration of serial sample collection is biomarker-dependent and cannot be standardized at this time. Information regarding cerebrospinal fluid guidelines and microdialysis guidelines can be found in appendices 3 and 4, respectively. Each of these best practice guidelines addresses the acquisition, processing, and storage of the samples in sufficient detail to promote standardization.
FUTURE DIRECTIONS
Although these recommendations and best practices are voluntary, their adoption will lead to a new standardization that will advance TBI research. To demonstrate the utility of these recommendations and best practices, we propose a pilot study to examine the feasibility of multicenter biomarker CDE collection across the broad spectrum of TBI. Implementation of biospecimen and biomarker best practices will also require outreach and education to inform and engage the TBI research community and solicit comments and feedback. The working group believes that the recommendations and best practices for TBI biospecimens and biomarkers will continue to evolve as the field advances and potential biomarkers will one day become core CDEs. Thus, there will be a need for ongoing support for the TBI CDE effort.
APPENDIX 1: DNA GUIDELINES FOR GENOMIC ANALYSES
I. Acquisition of blood biospecimens
A. Blood is collected through venipuncture by appropriately trained personnel. B. For isolation of genomic DNA from whole blood, collection of 5 to 20mL using EDTA-containing 
II. Local processing (serum)
A. Blood samples should be collected in vacutainers that contain no anticoagulant for the processing of serum. B. Samples should be sat upright at room temperature for 30 minutes to allow for clotting. They then should be spun at 4000rpm at room temperature for 5 to 7 minutes. The cleared serum should be pipetted and stored in aliquots of 1 to 2mL. C. Record the volume of each aliquot.
III. Local processing (plasma)
A. Blood samples should be collected in vacutainers that contain EDTA when preparing plasma. Previous research suggests that EDTA is the preferred anticoagulant because others may interfere with analyte detection. 19 i. The distinction between K2EDTA and K3EDTA and their concentrations should be assessed. See Goossens et al 20 for more details. B. Transport the original, unfrozen blood sample to the designated local proteomics laboratory as soon as possible. Freezing has significant adverse effects on plasma and its proteomic elements. C. If specimens must be stored before processing, the samples should sit on ice for 5 to 10 minutes. Samples should be spun at 4000rpm at room temperature for 5 to 7 minutes. Plasma should be pipetted and stored in aliquots of 500 L to 2mL. D. Record the volume of each aliquot.
IV. Local documentation and storage
A. Appropriate and complete documentation surrounding biospecimen collection, processing, and storage are essential and will influence the quality of research data to be obtained. B. Bar code identification of samples with an automated date and time stamp is recommended. C. Samples should be placed in nonfrost-free freezers at or below -80°C. Frost-free freezers go through freezethaw cycles that further damage the specimen. D. Centers at which samples are stored should institute a back-up plan for freezer failure (eg, dry ice or liquid nitrogen). An appropriate alarm system to support freezers for longtime storage is essential. E. An inventory system should be established for tracking provenance of samples, including the time of collection, processing, storage, and quality control procedures carried out on each sample.
V. Shipping A. Dry ice or cold packs must accompany the frozen specimen during air shipment. When dry ice is used, the transport time should be minimized given that dry APPENDIX 2 (Cont'd): PLASMA AND SERUM GUIDELINES FOR PROTEOMIC ANALYSES ice sublimates at a rate of 2 to 5 kg per 24 hours depending on the insulation of the shipment container. B. Consult the local agency for proper shipping options and certified transport materials. The International Air Transportation Association (http://www.iata.org) and the U.S. Department of Transportation (http://www.dot.gov) have legal requirements governing the packaging, labeling, and shipping of biospecimens.
i. Category A infectious substances are capable of causing permanent disability or life-threatening or fatal disease in humans or animals when exposure occurs. ii. Category B infectious substances (also "diagnostic specimens" or "clinical specimens") are infectious but do not meet the standard for Category A inclusion. iii. Exempt patient specimens have a minimal likelihood of containing pathogens. D. Temperature loggers can be used to monitor temperature in shipments of samples to provide confirmation and assurance that samples have been maintained at appropriate temperatures. Ideally, the first collection should be as close to the TBI as feasible (eg, 6h post-TBI), at a minimum frequency of every 6 hours for sufficient biokinetic studies. D. Collect 5mL of CSF in 1-mL fractions and place in ice bath. The first 1 or 2 fractions are sent for clinical laboratory analysis for cell count and protein and glucose measurements. Blood contamination of CSF is a significant confounder. Protein concentrations are 400-fold greater in plasma than CSF. 22 CSF is considered blood-contaminated if RBC counts are greater than 10 cells/L or if hemoglobin levels are greater than 30pg/mL CSF. 23 Brain specific proteins are typically present at low concentrations in CSF, with 80% of normal CSF protein mass originating from plasma. i. Artificial CSF ii. Sterile medical-grade normal saline B. The composition and source of the microdialysate must be specified in all data reporting.
IV. Sample acquisition
A. The microdialysate flow rate should be 0.3L/min so that it is theoretically possible to collect 18L during 1 hour. This flow rate assures near 100% analyte recovery for common low-molecular-weight analytes. B. Because of the extremely small sample volumes, the samples are sensitive to evaporation even though they are sealed in the microvials, and because microvials may contain different volumes, the effect of evaporation can vary between the samples. Characteristics of the collecting containers must be reported. C. Samples should be analyzed and/or stored promptly.
V. Analytes
A. The minimal essential data set consists of glucose, pyruvate, and lactate, with use of the calculated lactate/pyruvate ratio. B. Measurement of glycerol and glutamate is recommended. C. Determination of other analytes including markers of neuroinflammation such as cytokines, nitrate and nitrite as surrogates for nitric oxide, structural proteins such as glial fibrillary acidic protein, neurofilament, and tau and stress reactants such as beta-amyloid are all experimental. Analysis of these and other potential biomarkers should be encouraged but not required.
VI. Analyte stability during storage
A. The essential low-molecular-weight analytes are stable at -70°C. The samples should be stored at this temperature in containers designed to minimize evaporative losses. B. Analytes, particularly pyruvate, may not be stable at -20°C. Storage at this temperature is not acceptable with the exception of temporary holding for not more than 3 days. C. Determination of other analytes including markers of neuroinflammation such as cytokines, nitrate and nitrite as surrogates for nitric oxide, structural proteins such as GFAP, neurofilament, and tau and stress reactants such as beta-amyloid are all experimental. Analysis of these and other potential biomarkers should be encouraged but not required.
VII. Handling of samples at the time of analysis
A. If the samples have been frozen, then they must be thawed prior to analysis. It is important to recognize physicochemical events that may occur in the process of thawing that might cause analytic errors. As the samples thaw, the liquid phase will initially contain a very high concentration of salt and analytes. As the thawing progresses, the solution will be diluted by the melting ice. During this process, there is a risk that the thawed samples are nonhomogeneous; therefore, it is recommended that the samples be thawed and then agitated or centrifuged to assure homogeneous distribution of analyte.
